Chinese stocks: Internet pharmaceutical platform 1 Yaowang 111, Inc. (YI)

1Yaowang 111, Inc. (NYSE: YI) was founded in July 2010, formerly known as, formerly known as New Peak Group. It was changed to its current name in April 2018 and was formerly known as No.1 Yaowang. Headquartered in Pudong New Area, Shanghai, China, with 1,117 full-time employees (6/30/2018), it is an Internet medicine platform and one of the first legal online pharmacies in China to obtain the “Internet Drug Transaction License” issued by the State Food and Drug Administration. Provide customers with a one-stop “medicine + medicine” convenient experience.


1 Yaowang 111, Inc. (YI):

1Yaowang (formerly known as, the predecessor of, was established in July 2010 and belongs to the 111 Group. It is a pharmaceutical platform being used by a large number of users. It is also the first batch of China’s The legal online pharmacy of “Internet Drug Transaction License” provides customers with a one-stop “medicine + medicine” convenient experience.

1Yaowang has always been committed to using Internet thinking to cut into the digital and mobile medical and health fields, to solve the problem of “difficult medical treatment and expensive medicine” for Chinese people, and to create greater value for society.

Relying on 111 Group’s core advantages in cloud platform solutions, intelligent supply chain, big data, and medical professional capabilities, builds on platform operations, product procurement, supply chain management, medical services, customer experience, warehousing and distribution, etc. Played the core competitiveness.

Relying on the unique resources and platform advantages of source medicine and online e-commerce, is dedicated to benefiting customers. The same quality assurance of medicines and lower sales prices have attracted more and more patients to buy medicines online. Through direct supply cooperation with pharmaceutical manufacturers, reduces intermediate links in supply chain management and realizes an efficient and transparent management model. At the same time, it provides customers with genuine guarantees and safety guarantees.

At present, has cooperated with hundreds of domestic and foreign pharmaceutical companies such as Bayer , Pfizer , Eli Lilly , AstraZeneca , Tongrentang, Donge Ejiao, Johnson & Johnson , Anshiyou, Baiyunshan, Huiren Pharmaceutical, Besunyen, Silian Pharmaceutical, etc. Manufacturers have established long-term cooperative relationships to provide customers with hundreds of thousands of medical and health products covering Chinese and Western medicines, nourishing health care, vitamin calcium, contact lenses, medical equipment, cosmeceuticals and personal care.

Relying on the warehousing layout of 111 Group, provides customers with faster delivery methods and experience. Currently, 111 Group has established operations and storage centers in South China, East China, North China, and Southwest China covering the whole country, located in Guangzhou, Kunshan, Tianjin, and Chongqing. has a professional team of pharmacists to provide customers with one-on-one online medication consultation services, focusing on privacy protection, helping customers to choose drugs without worry, and purchase drugs with confidence. At the same time, provides customers with services such as online consultations and electronic prescriptions with the help of the team of physicians in the Internet hospital.

In addition, also provides customers with special shopping guides, nutrition matching advice and other special services, as well as various convenient services such as full order tracking, cash on delivery, and mobile POS swiping. In 2017,’s customer satisfaction rate exceeded 97%.

Since 2010, has successively won the “Top Ten Chinese Pharmaceutical E-Commerce Websites”, “Top Ten Pharmaceutical E-commerce Companies in China’s Pharmacy Value List”, “China Top 100 Chain Pharmacy Enterprises with Comprehensive Strength”, and “Zerotech Top 50 China “The Most Investment Value Enterprise”, “2016-2017 Shanghai E-commerce Demonstration Unit”, “Annual Most Influential Pharmaceutical E-commerce Brand”, “Guangdong Province Contract-abiding and Credit-abiding Enterprise for Six Consecutive Years (2012-2017)”, “China Life and Health Enterprise Unicorn Enterprise” and other honorary titles.

In addition to Shanghai Overseas, the 111 company has offices in Guangzhou, Wuhan, Beijing, Chengdu, Anshun and other places. In addition, it has a number of physical pharmacies in Guangzhou and other places. (From the official website)

As of June 30, 2018, 111, Inc. has a network of 12 offline retail pharmacies in Guangzhou, Shanghai, Tianjin and Kunshan under the brand name Yi Hao Pharmacy (No. 1 Pharmacy). The company provides services to pharmacies, pharmaceutical companies, medical professionals and consumers.

111 Group Encyclopedia:

111 Group is a leading company in China’s Internet medicine and health industry. It is committed to using the Internet model and way of thinking to change the status quo of “difficult to see a doctor and expensive medicine” for the Chinese public. 111 Group uses innovative Internet and IT technologies to provide online diagnosis and treatment, drug purchase and health management services, reduces intermediate links, optimizes the supply chain, and provides complete solutions, benefits and conveniences for the Chinese public to seek medical treatment and purchase drugs.

111 Group owns : B2C medicine platform “1 Medicine Network”, Internet hospital “1 Clinic”, B2B medicine platform “1 Medicine City”, through the innovative B2B2C model, fully realize B-end and C-end, online and offline , Self-operated and platform, integrated development of medicine and medicine, empowered by technology, to create China’s largest online and offline integrated medical and health platform, empowering doctors, pharmacies, hospitals, pharmaceutical companies, and drug distributors. It is the Internet One of the few unicorns in the medical and health industry. (From the official website)

1 Yaowang 111, Inc. (YI) investment:

1 Yaowang 111, Inc. (NYSE: YI) submitted its IPO prospectus on 8/15/2018 and listed on the New York Stock Exchange on 9/12/2018. The issue price was US$14.00, 7.175 million shares were issued, and US$104.5 million was raised. , JP Morgan / Citigroup / CICC joint underwriting. On the same day, there was also a Chinese concept stock- Weilai Automobile .

Notify of
Inline Feedbacks
View all Intels

Aircraft structure company: LMI Aerospace (LMIA) (1948)

Media/Communications/Entertainment: GCI Liberty, Inc. (GLIBA)